Purple Biotech Ltd. PPBT
Annual
Quarterly
FY2020 · ended Dec 31, 2020 · Revenue $1.00M, +0.0% YoY · Filed Mar 3, 2023
Purple Biotech Ltd. (PPBT) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$5.7 million. As of Dec 31, 2025 it held $8.7 million in cash and investments and $244,000 in total debt.
Revenue
$1.00M
+0.0% vs prior year
Net income
$-26.49M
-264.0% vs prior year
Operating cash flow
$-5.66M
+60.6% vs prior year
Free cash flow
$-5.66M
-1057.3% vs prior year
EPS
$0.03
-99.5% vs prior year
Dividend per share
None
Shares outstanding
1.86B
+259.5% vs prior year
Net cash
$8.47M
FY 2025
Operating margin
-1261.2%
FY 2020
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PPBT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Rehovot, Israel
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1614744
- Former names
- Kitov Pharma Ltd. (until Dec 10, 2020); Kitov Pharmaceuticals Holdings Ltd. (until Dec 21, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | — | — | -$22.3M | — | — |
| Net income | -$26.5M | -$7.3M | -$20.0M | -$21.8M | $18.5M |
| Diluted EPS | $0.03 | $4.99 | $17.96 | — | — |
| Operating cash flow | -$5.7M | -$14.4M | — | — | -$374,000 |
| Free cash flow | -$5.7M | — | — | — | -$489,000 |
| Total assets | $17.6M | $37.0M | $44.3M | $54.6M | $70.2M |
| Stockholders' equity | $9.7M | $32.9M | $34.3M | $47.1M | $65.1M |
| Cash and investments | $8.7M | $7.4M | $14.5M | $15.0M | $10.9M |
| Total debt | $244,000 | $183,000 | $376,000 | $592,000 | $877,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 5, 2026 | Oct 5, 2026 |
| 6-K | Current report (foreign issuer) | Sep 9, 2026 | Sep 9, 2026 |
| 6-K | Current report (foreign issuer) | Sep 2, 2026 | Sep 2, 2026 |
| 6-K | Current report (foreign issuer) | Aug 10, 2026 | Aug 10, 2026 |
| 6-K | Current report (foreign issuer) | Aug 7, 2026 | Aug 7, 2026 |
| 6-K | Current report (foreign issuer) | Jul 29, 2026 | Jul 29, 2026 |
All 576 Purple Biotech Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.